Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002282932 | SCV002570968 | likely pathogenic | Hermansky-Pudlak syndrome | 2022-07-22 | criteria provided, single submitter | clinical testing | Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 2-17 in the HPS3 gene. A presumed nomenclature of c.(217+1_218-1)_(*975_?)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result in a frameshift in the HPS3 gene, a known mechanism of disease. The variant was absent in 21692 control chromosomes (gnomAD, Structural Variants dataset). To our knowledge, no occurrence of c.(217+1_218-1)_(*975_?)del in individuals affected with Hermansky-Pudlak Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. One ClinVar submitter (evaluation after 2014) cites the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |